Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT03399799
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
This study is testing a new medicine called Talquetamab to make sure it is safe. They want to figure out the right amount of medicine to give to people without hurting them (Part 1) and then test it more at that amount (Part 2).
This study is testing a new medicine called Talquetamab to make sure it is safe. They want to figure out the right amount of medicine to give to people without hurting them (Part 1) and then test it more at that amount (Part 2).
Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to characterize the safety of Talquetamab and to determine the recommended Phase 2 dose(s) (RP2Ds) and dosing schedule assessed to be safe for Talquetamab (Part 1 \[Dose Escalation\]) and to further characterize the safety of Talquetamab at the recommended Phase 2 dose(s) (RP2Ds) (Part 2 \[Dose Expansion\]).
The purpose of this study is to characterize the safety of Talquetamab and to determine the recommended Phase 2 dose(s) (RP2Ds) and dosing schedule assessed to be safe for Talquetamab (Part 1 \[Dose Escalation\]) and to further characterize the safety of Talquetamab at the recommended Phase 2 dose(s) (RP2Ds) (Part 2 \[Dose Expansion\]).
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
